Radioprotective effect of amifostine on cells from cancer prone patients and healthy individuals studied by the G2 and PCC assays

International Journal of Radiation Biology

Volumn 79, Issue 10, 2003, Pages 831-838

  Manola, K N ^a   Terzoudi, G I ^a   Dardoufas, C E ^b   Malik, S I ^a   Pantelias, G E ^a  

^a Laboratory of Health Physics and Environmental Hygiene   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE;

ANIMAL CELL; ARTICLE; ATAXIA TELANGIECTASIA; BIOASSAY; CANCER PATIENT; CANCER SUSCEPTIBILITY; CELL CYCLE G2 PHASE; CELL PROTECTION; CHROMATID ABERRATION; CHROMOSOME BREAKAGE; CONTROLLED STUDY; DNA REPAIR; DRUG EFFECT; DRUG MECHANISM; GAMMA IRRADIATION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; NONHUMAN; PREMATURE CHROMOSOME CONDENSATION; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION PROTECTION; RADIATION RESPONSE;

AMIFOSTINE; ATAXIA TELANGIECTASIA; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; G2 PHASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHOCYTES; NEOPLASMS; PRECANCEROUS CONDITIONS; RADIATION PROTECTION; RADIATION TOLERANCE; RADIATION-PROTECTIVE AGENTS; REFERENCE VALUES;

ANIMALIA;

EID: 0344121640     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/09553000310001610222     Document Type: Article

References (36)

1. BARIA, K., WARREN, C., EDEN, O. B., ROBERTS, S. A., WEST, C. M. and SCOTT, D., 2002, Chromosomal radiosensitivity in young cancer patients: possible evidence of genetic predisposition. International Journal of Radiation Biology, 78, 341-346.
2. BARIA, K., WARREN, C., ROBERTS, S. A., WEST, C. M. and SCOTT, D., 2001, Chromosomal radiosensitivity as a marker of predisposition to common cancers. British Journal of Cancer, 6, 892-896.
3. BORGMANN, K., ROPER, B., EL-AWADY, R., BRACKROCK, S., BIGALKE, M., DORK, T., ALBERTI, W., DIKOMEY, E. and DAHM-DAPHI, J., 2002, Indicators of late normal tissue response after radiotherapy for head and neck cancer: fibroblasts, lymphocytes, genetics, DNA repair, and chromosome aberrations. Radiotherapy and Oncology, 64, 141-152.
4. CAPIZZI, R. L., 1996, The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). European Journal of Cancer, 32A(SuppL), S5-S16.
5. CAPIZZI, R. L., 1999, The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Seminars in Oncology. 26(2 Suppl. 7), 3-21.
6. CASTIGLIONE, F., DALLA MOLA, A. and PORCILE, G., 1999, Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine. Tumorigenesis, 85, 85-91.
7. COCO-MARTIN, J. M. and BEGG, A. C., 1997, Detection of radiation-induced chromosome aberrations using fluorescence in situ hybridization in drug-induced premature chromosome condensations of tumour cell lines with different radiosensitivities. International Journal of Radiation Biology, 71, 265-273.
8. DURANTE, M., FURUSAWA, Y. and GOTOH, E., 1998, A simple method for simultaneous interphase-metaphase chromosome analysis in biodosimetry. International Journal of Radiation Biology, 74, 457-462.
9. GOTOH, E., KAWATA, T. and DURANTE, M., 1999, Chromatid break rejoining and exchange aberration formation following γ-ray exposure: analysis in G2 human fibroblasts by chemically induced premature chromosome condensation. International Journal of Radiation Biology, 75, 1129-1135.
10. GRDINA, D. J., MURLEY, J. S. and KATAOKA, Y., 2002b, Radioprotectants: current status and new directions. Oncology, Suppl. 2, 2-10.
11. GRDINA, D. J., MURLEY, J. S., KATAOKA, Y. and EPPERLY, W., 2002a, Relationships between cytoprotection and mutation prevention by WR-1065. Military Medicine, 167(2 Suppl), 51-53.
12. GRDINA, D. J. and NAGY, B, 1986, The effect of 2-[(aminopropyl)amino] ethanethiol(WR1065) on radiation-induced DNA damage and repair and cell progression in V79 cells. British Journal of Cancer, 54, 933-941.
13. GRDINA, D. J. and SIGDESTADT, C. P., 1989, Radiation protectors; the unexpected benefits. Drug Metabolism Reviews, 20, 13-42.
14. GRIGGS, J. J., 1998, Reducing the toxicity of anticancer therapy: new strategies. Leukemia Research, 22(Suppl. 1), S27-33.
15. HOSPERS, G. A., EISENHAUER, E. A. and DE VRIES, E. G., 1999, The sulfhydryl containing compounds WR-2721 and glutathione as radio-and chemoprotective agents. A review, indications for use and prospects. British Journal of Cancer, 80, 629-638.
16. KATAOKA, Y., PERRIN, J., HUNTER, N., MILLAS, L. and GRDINAD, J., 1996, Antimutagenic effects of amifostine: clinical implications. Seminars in Oncology, 23(Suppl. 8), 53-57.
17. LINDEGAARD, J. C. and GRAU, C., 2000, Has the outlook improved for Amifostine as a clinical radioprotector? Radiotherapy and Oncology, 57, 113-118.
18. LITTLEFIELD, L. G., JOINER, E. E., COLYER, S. P., SALLAM, F. and FROME, E. L., 1993, Concentration-dependent protection against X-ray-induced chromosome aberrations in human lymphocytes by the WR-1065. Radiation Research, 133, 88-93.
19. MARZATICO, F., PORTA, C., MORONI, M., BERTORELLI, L., BORASIO, E., FINOTTI, N., PANSARASA, O. and CASTAGNA, L., 2000, In vitro antioxidant properties of amifostine (WR-2721, Ethyol). Cancer Chemotherapy and Pharmacology, 45, 172-176.
20. NORTH, S., EL-GHISSASSI, F., PLUQUET, O., VERHAEGH, G. and HAINAUT, P., 2000, The cytoprotective aminothiol WR1065 activates p21 waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene, 24, 1206-1214.
21. PANTELIAS, G. E., 1986, Radiation-induced cytogenetic damage in relation to changes in interphase chromosome conformation. Radiation Research, 105, 341-350.
22. PANTELIAS, G. E. and MAILLIE, H. D., 1983, A simple method for premature chromosome condensation induction in primary human and rodent cells using polyethylene glycol. Somatic Cell Genetics, 9, 533-547.
23. PANTELIAS, G. E. and MAILLIE, H. D., 1985, Direct analysis of radiation-induced chromosome fragments and rings in unstimulated human peripheral blood lymphocytes by means of the premature chromosome condensation technique. Mutation Research, 149, 67-72.
24. PETERS, G. J. and VAN DER VIJGH, W. J. F., 1995, Protection of normal tissue from cytotoxic effects of chemotherapy and radiation by amifostine (WR-27-21): Preclinical aspects. European Journal of Cancer, 31A(Suppl. 1), S1-S7.
25. SANFORD, K. K., PARSHAD, R., GANTT, R. E., TARONE, R. E., JONES, G. M. and PRICE, F. M., 1989, Factors affecting and significance of G2 chromatin radiosensitivity and predisposition to cancer. International Journal of Radiation Biology, 55, 963-968.
26. SANTINI, V. and GILES, F. J., 1999, The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica, 84, 1035-1042.
27. SCHWARTZ, J. L., GIOVANAZZI, S. M., KARRISON, T., JONES, C. and GRDINA, D. J., 1988, 2-[(Aminopropyl)amino] ethanethiol-mediated reductions in 60Co gamma-ray and fission-spectrum neutron-induced chromosome damage in V79 cells. Radiation Research, 113, 145-154.
28. SCOTT, D., SPREADBOROUGH, A. R., ROBERTS, L. A. and MOORE, C. J., 1996, Chromosomal radiosensitivity in G2-phase lymphocytes as an indicator of cancer predisposition. Radiation Research, 145, 3-16.
29. SHAW, L. M., BONNER, H. and LIEBERMAN, R., 1996, Pharmacokinetic profile of amifostine. Seminars in Oncology, 23(4 Suppl. 8), 18-22.
30. SHEN, H., CHEN, Z. J., ZILFOU, J. T., HOPPER, E., MURPHY, M. and TEW, K. D., 2001, Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. Journal of Pharmacology and Experimental Therapeutics, 297, 1067-1073.
31. SHIGEMATSU, N., SCHWARTZ, J. L. and GRDINA, D. J., 1994, Protection against radiation-induced mutagenesis at the HPRT locus by spermine and N,N-(diothiodi-2,1-ethanediyl), bis-1,3-propanediamine (WR-33278). Mutagenesis, 9, 355-360.
32. SMOLUK, G. D., FAHEY, R. C., CALABRO-JONES, P. M. and AGUILERA, J. A., 1988, Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Research, 48, 3641-3647.
33. TERZOUDI, G. I., JUNG, T., HAIN, J., VROUVAS, J., MARGARITIS, K., DONTA-BAKOYIANNI, C., MAKROPOULOS, V., ANGELAKIS, PH. and PANTELIAS, G. E., 2000, Increased G2 chromosomal radiosensitivity in cancer patients: the role of cdk1/ cyclinB activity level in the mechanisms involved. International Journal of Radiation Biology, 76, 607-616.
34. TERZOUDI, G. I. and PANTELIAS, G. E., 1997, Conversion of DNA damage in response to cell cycle regulation of chromatin condensation after irradiation. Mutagenesis, 12, 271-276.
35. WOLFF, S. and ARUTYUNYAN, R., 1979, The apparent decrease in thiotepa induced chromosome aberrations in human lymphocytes caused by an effect of WR2721 on the cell cycle as found by the definitely determined division method. Environmental Mutagenesis, 1, 5-13.
36. XINBO, C., PANTELIAS, G. E., OKAYASU, R., CHEONG, N. G. E. and ILIAKIS, G., 1993, Mitosis-promoting factor activity of inducer mitotic cells may affect radiation yield of interphase chromosome breaks in the premature chromosome condensation assay. Cancer Research, 53, 5592-5596.